Atrium Therapeutics, Inc. (RNA)

NASDAQ: RNA · Real-Time Price · USD

7.57

-0.10 (-1.30%)

Oct 19, 2026, 10:42 AM EDT - Market open

Atrium Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	35.84	18.62	10.9	9.76
Revenue Growth	228.87%	70.85%	11.60%	-
Gross Profit	-20.2	-25.65	-8.3	-2.89
Operating Income	-69.21	-49.63	-13.22	-6.39
Net Income	-65.99	-49.5	-25.12	-6.39
Earnings Per Share	-3.86	-3.19	-	-
EPS Growth	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Investments	263.9	0	0	0
Total Debt	1.68	3.67	6.8	9.85
Net Cash (Debt)	262.22	-3.67	-6.8	-9.85
Net Cash Growth	-	-	-	-
Net Cash Per Share	15.33	-0.24	-	-

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Operating Cash Flow	-53.19	-41.13	-22.55	56.39
Capital Expenditures	-3.31	-1.45	-0.27	-0.32
Free Cash Flow	-56.5	-42.57	-22.82	56.07
Free Cash Flow Growth	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Gross Margin	-56.37%	-137.76%	-76.19%	-29.59%
Operating Margin	-193.13%	-266.57%	-121.30%	-65.40%
Pretax Margin	-184.54%	-266.64%	-121.28%	-65.39%
Profit Margin	-184.15%	-265.88%	-230.54%	-65.39%
FCF Margin	-157.66%	-228.67%	-209.41%	574.25%